Synthesis of novel 225Ac-Sn particles was described for the
first time. Detailed experimental and stability studies were successfully
exhibited. Treatment of excess amount of SnCl2 with 0.2 mCi 225Ac
furnished highly stable 225Ac tin colloid with 90% of radiochemical
yield (RCY) at optimized reaction condition. R-TLC analyses indicated 95% of
radiochemical purity (RCP). Stability studies showed that colloidal structure
also retained free daughter radionuclides formed by the 225Ac decay
chain. 225Ac tin colloids could be ideal nanocarriers for localized
cell killing due to high linear energy transfer and prevention of free
radioisotope daughters.
References
[1]
Fellinger, K. and Schmid, J. (1952) Local Therapy of Rheumatic Diseases. Wiener Zeitschrift fur innere Medizin, 33, 351-363.
[2]
Schneider, P., Farahati, J. and Reiners, C. (2005) Radiosynovectomy in Rheumatology, Orthopedics, and Hemophilia. Journal of Nuclear Medicine, 46, 48-54.
[3]
Szerb, I., Gál, T., Mikó, I. and Hangody, L. (2021) Radiosynoviorthesis in the Treatment of Posttraumatic Joint Bleedings of Hemophilic Patients (Concerning Hip, Knee and Ankle Joints)-Hungarian Experience. Injury, 52, 53-56. https://doi.org/10.1016/j.injury.2020.02.054
[4]
Bagheri, R., Afarideh, H., Maragheh, M.G., Shirmardi, S.P. and Samanı, A.B. (2015) Study of Bone Surface Absorbed Dose in Treatment of Bone Metastases via Selected Radiopharmaceuticals: Using MCNP4C Code and Available Experimental Data. Cancer Biotherapy and Radiopharmaceuticals, 30, 174. https://doi.org/10.1089/cbr.2014.1730
[5]
Knut, L. (2015) Radiosynovectomy in the Therapeutic Management of Arthritis. World Journal of Nuclear Medicine, 14, 10. https://doi.org/10.4103/1450-1147.150509
[6]
Koc, B., Kılıcoglu, O. and Turkmen, C. (2020) Prognostic Factors of Radiosynovectomy in Haemophilia Patients with Inhibitors: Survival Analysis in a 19-Year Period. Haemophilia, 26, 855-860. https://doi.org/10.1111/hae.14091
[7]
Lee, E.B., Shin, K.C., Lee, Y.J., Cheon, G.J. Jeong, J.M., Son, M.W. and Song, Y.W. (2003) 188Re-Tin-Colloid as a New Therapeutic Agent for Rheumatoid Arthritis. Nuclear Medicine Communications, 24, 689-696. https://doi.org/10.1097/00006231-200306000-00012
[8]
Farahati, J., Kazek, S., Maric, I., Soestwoehner, T., Kalle, P., Costa, P.F., Jentzen, W., Stein, L., Jalilian, A., Kumm, D., Bockisch, A. and Herrmann, K. (2019) Post-Radi- osynovectomy Imaging Utilizing Erbium-169 Citrate. Applied Radiation and Isotopes, 154, Article ID: 108853. https://doi.org/10.1016/j.apradiso.2019.108853
[9]
Kampen, W.U., Brenner, W., Czech, N. and Henze, E. (2002) Intraarticular Application of Unsealed Beta-Emitting Radionuclides in the Treatment Course of Inflammatory Joint Diseases. Current Medicinal Chemistry, 1, 77-87. https://doi.org/10.2174/1568014024606502
[10]
Jha, P., Arora, G., Shamim, S.A., Mukherjee, A., Gautam, D., Ballal, S., Kumar, U., Ansari, T.M. and Bal, C. (2018) Lutetium-177 Tin Colloid Radiosynovectomy in Patients with Inflammatory Knee Joint Conditions Intractable to Prevailing Therapy. Nuclear Medicine Communications, 39, 803-808. https://doi.org/10.1097/MNM.0000000000000871
Elgqvist, J., Frost, S., Pouget, J.P. and Albertsson, P. (2014) The Potential and Hurdles of Targeted Alpha Therapy—Clinical Trials and Beyond. Frontiers in Oncology, 3, Article No. 324. https://doi.org/10.3389/fonc.2013.00324
[13]
Robertson, A.K.H., Ramogida, C.F., Schaffer, P. and Radchenko, V. (2018) Development of 225Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences. Current Radiopharmaceuticals, 11, 156-172. https://doi.org/10.2174/1874471011666180416161908
[14]
Wilbur, S.D. (2011) Chemical and Radiochemical Considerations in Radiolabeling with α-Emitting Radionuclides. Current Radiopharmaceuticals, 4, 214-217. https://doi.org/10.2174/1874471011104030214
[15]
Nilsson, S., Larsen, R.H., Fosså, S.D., Balteskard, L., Borch, K.W., Westlin, J.E., Salberg, G. and Bruland, O.S. (2005) First Clinical Experience with Alpha-Emitting Radium-223 in the Treatment of Skeletal Metastases. Clinical Cancer Research, 11, 4451-4459. https://doi.org/10.1158/1078-0432.CCR-04-2244
[16]
Nilsson, S., Cislo, P., Sartor, O., Vogelzang, N.J., Coleman, R.E., O’Sullivan, J.M., Reuning-Scherer, J., Shan, M., Zhan, L. and Parker, C. (2016) Patient-Reported Quality-of-Life Analysis of Radium-223 Dichloride from the Phase III ALSYMPCA Study. Annals of Oncology, 27, 868-874. https://doi.org/10.1093/annonc/mdw065
[17]
Hallqvist, A., Bergmark, K., Bäck, T. andersson, H., Dahm-Kähler, P., Johansson, M., Lindegren, Jensen, S.H., Jacobsson, L., Hultborn, R., Palm, S. and Albertsson, P. (2019) Intraperitoneal α-Emitting Radioimmunotherapy with 211At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose Estimations. Journal of Nuclear Medicine, 60, 1073-1079. https://doi.org/10.2967/jnumed.118.220384
[18]
Delpassand, E., Tworowska, I., Shanoon, F., Nunez, R., Flores, L., Muzammil, A., Stallons, T., Saidi, A. and Torgue, J. (2019) First Clinical Experience Using Targeted Alpha-Emitter Therapy with Pb-212-DOTAMTATE (AlphaMedix TM) in Patients with SSTR(+) Neuroendocrine Tumors. Journal of Nuclear Medicine, 60, 559.
[19]
Kratochwil, C., Giesel, F.L., Bruchertseifer, F., Mier, W., Aposdolidis, C., Boll, R., Murphy, K., Haberkorn, U. and Morgestren, A. (2014) 213Bi-DOTATOC Receptor- Targeted Alpha-Radionuclide Therapy Induces Remission in Neuroendocrine Tumours Refractory to Beta Radiation: A First-in-Human Experience. European Journal of Nuclear Medicine and Molecular Imaging, 41, 2106-2119. https://doi.org/10.1007/s00259-014-2857-9
[20]
Kratchowil, C., Bruchertseifer, F., Giesel, F.L., Weis, M., Verburg, F.A., Mottaghy, F., Kopka, K., Apostolidis, C., Haberkorn, U. and Morgenstern, A. (2016) 225Ac- PSMA-617 for PSMA-Targeted-Radiation Therapy of Metastatic Castration-Resis- tant Prostate Cancer. Journal of Nuclear Medicine, 57, 1941-1944. https://doi.org/10.2967/jnumed.116.178673
[21]
Eryilmaz, K. and Kilbas, B. (2022) Detailed Chemistry Studies of 225Actinium Labeled Radiopharmaceuticals. Current Radiopharmaceuticals. https://doi.org/10.2174/1874471014666210528123936
[22]
Morgenstern, A., Apostolidis, C., Kratochwil, C., Sathekge, M., Krolicki, L. and Bruchertseifer, F. (2018) An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth. Current Radiopharmaceuticals, 11, 200-208. https://doi.org/10.2174/1874471011666180502104524
[23]
Trujillo-Nolasco, M., Morales-Avila, E., Cruz-Nova, P., Katti, K.V. and Ocampo- García, B. (2021) Nanoradiopharmaceuticals Based on Alpha Emitters: Recent Developments for Medical Applications. Pharmaceutics, 13, 1123. https://doi.org/10.3390/pharmaceutics13081123
[24]
Enrique, M.-A., Mariana, O.-R., Mirshojaei, S.F. and Ahmadi, A. (2015) Multifunctional Radiolabeled Nanoparticles: Strategies and Novel Classification of Radiopharmaceuticals for Cancer Treatment. Journal of Drug Targeting, 23, 191-201. https://doi.org/10.3109/1061186X.2014.988216
[25]
Viana, R.D.S., Costa, L.A.DM., Harmon, A.C., Gomes Filho, M.A., Falcão, E.H.L., Vicente, M.G.H., Junior, S.A. and Mathis, J.M. (2020) 177Lu-Labeled Eu-Doped Mesoporous SiO2 Nanoparticles as a Theranostic Radiopharmaceutical for Colorectal Cancer. ACS Applied Nano Materials, 3, 8691-8701. https://doi.org/10.1021/acsanm.0c01427
[26]
Cędrowska, E., Pruszynski, M., Majkowska-Pilip, A., Męczyńska-Wielgosz, S., Bruchertseifer, F., Morgenstern, A. and Bilewicz, A. (2018) Functionalized TiO2 Nanoparticles Labelled with 225Ac for Targeted Alpha Radionuclide Therapy. Journal of Nanoparticle Research, 20, 83. https://doi.org/10.1007/s11051-018-4181-y
[27]
Woodward, J., Kennel, S.J., Stuckey, A., Osborne, D., Wall, J., Rondinone, A.J., Standaert, R.F. and Mirzadeh, S. (2011) LaPO4 Nanoparticles Doped with Actinium225 that Partially Sequester Daughter Radionuclides. Bioconjugate Chemistry, 22, 766-776. https://doi.org/10.1021/bc100574f
[28]
Kruijff, R.M., Raavé, R., Kip, A., Molkenboer-Kuenen, J., Morgenstern, A., Bruchertseifer, F., Heskamp, S. and Denkova, A.G. (2019) The in Vivo Fate of 225Ac Daughter Nuclides Using Polymersomes as a Model Carrier. Scientific Reports, 9, Article No. 11671. https://doi.org/10.1038/s41598-019-48298-8
Kratochwil, C., Haberkorn, U. and Giesel, F.L. (2019) Radionuclide Therapy of Metastatic Prostate Cancer. Seminars in Nuclear Medicine, 49, 313-325. https://doi.org/10.1053/j.semnuclmed.2019.02.003
[31]
Parker, C., Lewington, V., Shore, N., Kratochwil, C., Levy, M., Lindén, O., Noordzij, W., Park, J. and Saad, F. (2018) Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review. JAMA Oncology, 4, 1765-1772. https://doi.org/10.1001/jamaoncol.2018.4044
[32]
Arora, G., Singh, M., Jha, P., Tripathy, S., Bal, C., Mukherjee, A. and Shamim, S.A. (2017) Formulation and Characterization of Lutetium-177-Labeled Stannous (Tin) Colloid for Radiosynovectomy. Nuclear Medicine Communications, 38, 587-592. https://doi.org/10.1097/MNM.0000000000000684
